115 related articles for article (PubMed ID: 16866906)
21. Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology.
Mahley RW; Huang Y
Acta Neurol Scand Suppl; 2006; 185():8-14. PubMed ID: 16866905
[TBL] [Abstract][Full Text] [Related]
22. Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease.
Bales KR
Neuropharmacology; 2010; 59(4-5):295-302. PubMed ID: 20079752
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotective pentapeptide CN-105 is associated with reduced sterile inflammation and improved functional outcomes in a traumatic brain injury murine model.
Laskowitz DT; Wang H; Chen T; Lubkin DT; Cantillana V; Tu TM; Kernagis D; Zhou G; Macy G; Kolls BJ; Dawson HN
Sci Rep; 2017 Apr; 7():46461. PubMed ID: 28429734
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides.
Miyata M; Smith JD
Nat Genet; 1996 Sep; 14(1):55-61. PubMed ID: 8782820
[TBL] [Abstract][Full Text] [Related]
25. Cognitive impairment in neurological diseases: lessons from apolipoprotein E.
Shi J; Han P; Kuniyoshi SM
J Alzheimers Dis; 2014; 38(1):1-9. PubMed ID: 23948926
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein E gene promoter polymorphisms in Alzheimer's disease.
Bullido MJ; Valdivieso F
Microsc Res Tech; 2000 Aug; 50(4):261-7. PubMed ID: 10936877
[TBL] [Abstract][Full Text] [Related]
27. [How ApoE regulates blood-brain barrier integrity].
Gosselet F
Med Sci (Paris); 2012 Nov; 28(11):920-3. PubMed ID: 23171891
[No Abstract] [Full Text] [Related]
28. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
29. Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.
Yao J; Petanceska SS; Montine TJ; Holtzman DM; Schmidt SD; Parker CA; Callahan MJ; Lipinski WJ; Bisgaier CL; Turner BA; Nixon RA; Martins RN; Ouimet C; Smith JD; Davies P; Laska E; Ehrlich ME; Walker LC; Mathews PM; Gandy S
J Neurochem; 2004 Aug; 90(4):1011-8. PubMed ID: 15287908
[TBL] [Abstract][Full Text] [Related]
30. Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks.
Bour A; Grootendorst J; Vogel E; Kelche C; Dodart JC; Bales K; Moreau PH; Sullivan PM; Mathis C
Behav Brain Res; 2008 Nov; 193(2):174-82. PubMed ID: 18572260
[TBL] [Abstract][Full Text] [Related]
31. Apolipoprotein E increases cell association of amyloid-β 40 through heparan sulfate and LRP1 dependent pathways.
O'Callaghan P; Noborn F; Sehlin D; Li JP; Lannfelt L; Lindahl U; Zhang X
Amyloid; 2014 Jun; 21(2):76-87. PubMed ID: 24491019
[TBL] [Abstract][Full Text] [Related]
32. Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models.
Huang Y
Biochem Soc Trans; 2011 Aug; 39(4):924-32. PubMed ID: 21787325
[TBL] [Abstract][Full Text] [Related]
33. Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease.
Bana L; Minniti S; Salvati E; Sesana S; Zambelli V; Cagnotto A; Orlando A; Cazzaniga E; Zwart R; Scheper W; Masserini M; Re F
Nanomedicine; 2014 Oct; 10(7):1583-90. PubMed ID: 24333591
[TBL] [Abstract][Full Text] [Related]
34. Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior.
Grootendorst J; Bour A; Vogel E; Kelche C; Sullivan PM; Dodart JC; Bales K; Mathis C
Behav Brain Res; 2005 Apr; 159(1):1-14. PubMed ID: 15794991
[TBL] [Abstract][Full Text] [Related]
35. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice.
Fullerton SM; Shirman GA; Strittmatter WJ; Matthew WD
Exp Neurol; 2001 May; 169(1):13-22. PubMed ID: 11312553
[TBL] [Abstract][Full Text] [Related]
36. Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology.
Hartman RE; Wozniak DF; Nardi A; Olney JW; Sartorius L; Holtzman DM
Exp Neurol; 2001 Aug; 170(2):326-44. PubMed ID: 11476599
[TBL] [Abstract][Full Text] [Related]
37. The endosomal trafficking of apolipoprotein E3 and E4 in cultured human brain neurons and astrocytes.
DeKroon RM; Armati PJ
Neurobiol Dis; 2001 Feb; 8(1):78-89. PubMed ID: 11162242
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of ApoE-mimetic peptides in CNS disorders: Current perspective.
Ahmed S; Pande AH; Sharma SS
Exp Neurol; 2022 Jul; 353():114051. PubMed ID: 35314147
[TBL] [Abstract][Full Text] [Related]
39. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated.
Tolar M; Marques MA; Harmony JA; Crutcher KA
J Neurosci; 1997 Aug; 17(15):5678-86. PubMed ID: 9221767
[TBL] [Abstract][Full Text] [Related]
40. Apolipoprotein E may be a critical factor in hormone therapy neuroprotection.
Struble RG; Cady C; Nathan BP; McAsey M
Front Biosci; 2008 May; 13():5387-405. PubMed ID: 18508594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
